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Abstract
Background: Duchenne muscular dystrophy (DMD) is an inherited lethal muscle wasting disease characterized by
cycles of degeneration and regeneration, with no effective therapy. Growth differentiation factor 11 (GDF11), a member
of the TGF-β superfamily and myostatin homologous, has been reported to have the capacity to reverse age-related
skeletal muscle loss. These initial findings led us to investigate the ability of GDF11 to promote regeneration in the
context of muscular dystrophy and determine whether it could be a candidate to slow down or reverse the disease
progression in DMD.
Results: Here, we delivered recombinant GDF11 (rGDF11) to dystrophin-deficient mice using the intra-peritoneal
route for 30 days and evaluated histology and function in both steady-state and cardiotoxin-injured muscles. Our
data confirmed that treatment with rGDF11 resulted in elevated levels of this factor in the circulation. However,
this had no effect on muscle contractility nor on muscle histology. Moreover, no difference was found in the number
of regenerating myofibers displaying centrally located nuclei. On the other hand, we did observe increased collagen
content, which denotes fibrosis, in the muscles of rGDF11-treated dystrophic mice.
Conclusions: Taken together, our findings indicate no beneficial effect of treating dystrophic mice with rGDF11 and
raise caution to a potential harmful effect, as shown by the pro-fibrotic outcome.
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Background
Duchenne muscular dystrophy (DMD), the most common
muscular dystrophy in the young, is characterized by pro-
gressive muscle wasting, in which skeletal muscle fibers are
replaced by nonfunctional fibrotic and connective tissue
[1]. DMD is caused by mutations in the X-linked dys-
trophin gene, which is an essential element for the main-
tenance of muscle fiber integrity [2]. Dystrophin and its
associated proteins play an important role in protecting
myofibers from contraction-induced damage. Loss of dys-
trophin leads to destabilization of the extracellular mem-
brane resulting in rapid and continuous damage of the
structural integrity of myofibers [3]. Boys with DMD usu-
ally exhibit progressive motor difficulties and muscle
wasting, and as a result, patients are wheelchair-bound by
their teens, with eventual death due to cardiorespiratory
insufficiency [4]. Current therapeutic methods are only pal-
liative as to date no effective treatment is available for
DMD, or any type of muscular dystrophy.
Growth differentiation factor 11 (GDF11), a member of
the transforming growth factor β (TGF-β) superfamily,
has been recently described to promote muscle regener-
ation in the context of aging [5]. GDF11 is highly homolo-
gous to myostatin, another TGF-β member also known as
GDF8, sharing 89 % sequence identity throughout the ma-
ture active region. Accordingly, GDF11 and myostatin
share the same receptors and similar signaling pathways
[6, 7]. Despite this likeness, the aforementioned study sug-
gested opposite effects to these ligands on skeletal muscle
regeneration. Whereas myostatin has a well-known inhibi-
tory effect on muscle growth and differentiation [8–11],
this study demonstrated that reduced circulating levels of
GDF11 are linked to age-associated muscle loss, also
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known as sarcopenia, and that increasing in its levels in old
mice, upon a 30-day treatment with GDF11, reversed age-
related dysfunction of the mouse skeletal muscle [5]. A
similar anti-aging effect for GDF11 has also been reported
for the cardiac muscle [12] and brain [13], where this
growth factor has been demonstrated to reverse age-related
cardiac hypertrophy and neurologic defects, respectively.
We tested here whether GDF11 could ameliorate the
progression of the muscle wasting phenotype observed
in DMD by promoting muscle regeneration. For this,
rGDF11 was administered systemically to dystrophin-
deficient mdx mice for 30 days. To further test the
regenerative ability of GDF11-treated mice, we damaged
muscles from a cohort of treated and control mdx mice
with cardiotoxin (CTX). Our findings show that increased
levels of GDF11 in dystrophic mice have no effect on skel-
etal muscle regeneration and function. In fact, we observed
evidence of fibrosis in GDF11-treated mice, as shown by
the higher levels of collagen deposition in the tibialis anter-
ior muscle, raising caution to the use of GDF11 in DMD.
Methods
Mice
All animal studies were performed according to protocols
approved by the University of Minnesota Institutional Ani-
mal Care and Use Committee. Five-week-old male mdx
mice (C57BL/10ScSn-Dmdmdx/J; stock number 001801),
purchased from Jackson Laboratories (Bar Harbor, ME,
http://www.jax.org), were treated with GDF11 or vehicle,
as detailed below. In a cohort of these mice, we promoted
muscle injury by injecting 15 μl of CTX (10 μM, Sigma)
into the tibialis anterior (TA) muscle.
rGDF11 dosing and injections
We used the protocol used in the previous report for
sarcopenia [5]. rGDF11 stock solution was prepared by
dissolving it in water containing 0.1 % BSA and kept at
pH 3.8 with HCL, according to manufacturer’s instruc-
tions. Dystrophic mice were given a daily single intraper-
itoneal (IP) injection of either rGDF11 (PeproTech, Inc.)
at 0.1 mg/kg or vehicle (water containing 0.1% BSA pH
3.8; at the same volume as GFD11) for 30 days. After
30 days, most mice were analyzed. At this point, a co-
hort of treated mice was muscle damaged by receiving
15 μl of CTX (10 μM, Sigma) into the TA. Muscle
regeneration was evaluated 10 days later. During the 10-
day period, this cohort of mdx mice continued to receive
daily IP injections of rGDF11 or vehicle.
Muscle histology
For histology, the TA and diaphragm muscles were har-
vested, embedded in OCT compound (Leica Biosystems),
and then frozen in isopentane cooled in liquid nitrogen.
Serial 10 μm cryosections were collected. For quantification
of myofiber size and numbers, sections were stained for
laminin. Muscle sections were fixed in 4 % PFA for 30 min,
washed three times with PBS, blocked with 5 % BSA in PBS
for 1 h at room temperature (RT), and then incubated
with rabbit anti-laminin antibody (1:400; Sigma) over-
night at 4 °C overnight. The following day, slides were
washed three times in PBS and then stained with goat
Alexa-555 anti-rabbit secondary antibody (Invitrogen)
for 45 min at RT. To stain nuclei, we used ProLong®
Gold Antifade reagent along with DAPI (molecular
probes). Hematoxylin and eosin (H&E) staining was
used for assessment of centrally located nuclei myofi-
bers. Masson’s trichrome staining was utilized to detect
collagen content (Polysciences, Inc.). Fiji ImageJ soft-
ware was used to quantify myofiber size and numbers,
as well as muscle cross-sectional area. To quantify the
collagen, the colors from the figure were split and a
threshold was used to identify the blue staining. Then,
the complete muscle section was selected as a region of
interest, and the percentage of area depicted by the
threshold (equivalent to the collagen area) was mea-
sured also using ImageJ software.
Muscle preparation for mechanical studies
For the measurement of contractile properties, mice were
anesthetized with ketamine/xylazine (80 mg/kg) and the
intact TA muscles were dissected and placed in an experi-
mental organ bath filled with mammalian Ringer solution
containing (mM): NaCl 120.5; NaHCO3 20.4; glucose 10;
KCl 4.8; CaCl2 1.6; MgSO4 1.2; NaH2PO4 1.2; pyruvate
1.0, adjusted to pH 7.4. The chamber was perfused con-
tinuously with 95 % O2–5 % CO2 and maintained at a
temperature of 25 °C. The muscles were stimulated by an
electric field generated between two platinum electrodes
placed longitudinally on either side of the muscle (square
wave pulses 25 V, 0.2 ms in duration, 150 Hz). The mus-
cles were adjusted to the optimum length (Lo) for the
development of isometric twitch force, and a 5-min recov-
ery period was allowed between stimulations. Optimal
muscle length (Lo) and stimulation voltage (25 V) were
determined from micromanipulation of muscle length and
a series of twitch contractions that produced maximum
isometric twitch force. For measuring fatigue time, mus-
cles were stimulated for 1 min and the time for force to
decline to 30 % of Fo was measured. In brief, after deter-
mination of Lo and measurement of maximum isometric
tetanic force, total muscle cross-sectional area (CSA) was
calculated by dividing muscle mass (mg) by the product of
muscle length (mm) and 1.06 mg/mm3, the density of
mammalian skeletal muscle. Specific force (sFo) was de-
termined by normalizing maximum isometric tetanic force
(F0) to CSA. All of the mdx mice used for muscle physi-
ology were also analyzed for histopathology.
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Fig. 1 Histological analysis of the TA muscles isolated from mdx mice that had been treated with rGDF11 or vehicle. a Representative images of
the TA muscles stained with H&E from mice treated with rGDF11 or vehicle (upper panels). Another cohort of mice treated with rGDF11 or vehicle
was injured with cardiotoxin at day 30 and analyzed 10 days later (lower panels). b The percentage of centrally nucleated fibers was not altered
upon rGDF11 treatment in mice with or without cardiotoxin injury. As expected, the cardiotoxin injury increased the percentage of centrally nucleated
fibers. Treatment with GDF11 resulted in increased numbers of myofibers when compared to vehicle-treated mice (c) but did not affect the cross-sectional
area frequency distribution (d). Quantification was performed in the entire cross sections of the tibialis anterior muscles. Both rGDF11- and vehicle-treated
mice show leftward shift in frequency distribution. ≤200 μm2 myofibers were the largest group, and CTX injury increased the frequency of this group,
irrespective of GDF11. Fiji ImageJ software was used to determine number and size of myofibers. Scale bar= 100 μm. *p< 0.05, **p< 0.01, ***p< 0.001,
****p< 0.0001
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Western blot analysis
Plasma samples were collected from rGDF11 and
vehicle-treated mdx mice, as previously described [14],
and quantified with the Bradford regent (Sigma). Briefly,
samples were diluted in Laemmli buffer and boiled for
10 min at 100 °C. Equal amounts (75 μg) of protein from
Fig. 2 Histological analysis of the diaphragm muscle isolated from mdx treated with rGDF11 or vehicle. a Representative images of the
diaphragm muscle using H&E staining from mice treated with rGDF11 or vehicle. The treatment with GDF11 did not alter the percentage of
centrally nucleated fibers. b Representative images of the diaphragm muscle using Masson’s trichrome staining from mice treated with rGDF11 or
vehicle. No differences were observed in terms of the percentage of fibrotic tissue upon rGDF11 treatment as determined by the quantification
of the blue staining area (b). Fiji ImageJ software was used to quantify the percentage of collagen area. Scale bar = 100 μm
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each single mouse were loaded onto 4–20 % gradient
mini-PROTEAN® TGX Stain-Free™ gels (BioRad Labs).
Proteins were transferred onto polyvinyl difluoride
(PVDF) membranes (Millipore), which were then blocked
in BSA 5 % Tris-buffered saline (TBS) with 0.05 % Tween-
20 (TBST) for 1 h at RT. Membranes were incubated
with rabbit anti-GDF11 antibody (1:1000, Abcam) over-
night at 4 °C. The following day, these were incubated
with horseradish peroxidase (HRP)-conjugated second-
ary antibody (GE healthcare). Proteins were detected by
Pierce enhanced chemiluminescence (ECL) substrate
(Thermo Scientific).
Statistics analysis
One-way or two-way analysis of variance (ANOVA) was
used to analyze differences. When significant (p < 0.05),
this was followed by the Tukey post hoc analysis.
Results and discussion
rGDF11 treatment has no effect on the muscle
regeneration of mdx mice
To determine the effect of GDF11 treatment on muscle re-
generation in the context of muscular dystrophy, we treated
mdx mice for at least 30 days with GDF11 (n = 16) or ve-
hicle (n = 13). As expected, the higher levels of GDF11 were
Fig. 3 Assessment of muscle function. Isometric tetanic contraction was assessed in the isolated TA muscles from GDF11- and vehicle-injected
mdx mice, in the presence or absence of CTX injury. No significant changes were observed in absolute force (F0) (a), specific force (sF0) (b), and
fatigue index (c). No changes were observed in muscle weight or CSA (d, e, respectively)
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detected in the plasma of rGDF11-treated mice when
compared to controls, as shown by western blot ana-
lysis (Additional file 1). For this, we used the GDF11
antibody from Abcam, which as previously reported [15]
recognizes both the mature dimer (~25 kDa) and the
monomer (~12.5 kDa) of both recombinant GDF11 and
myostatin. We found increased levels of both, the mono-
mer and the dimer, in the plasma of rGDF11-treated mice
(Additional file 1). Nevertheless, by the end of the 30-day
treatment, morphological analysis of the TA muscles by
H&E staining showed no differences between GDF11- and
vehicle-treated groups in regard to the number of regener-
ating centrally nucleated myofibers in the TA (Fig. 1a,
upper panel, and b) and diaphragm (Fig. 2a) muscles. This
was also the case for the cohort in which the TA muscles
had been injured with CTX (Fig. 1a, lower panel, and b)
following the 30-day treatment (rGDF11 or vehicle, n = 5
and n = 4, respectively), which was analyzed 10 days later,
while receiving continuous administration of rGDF11 or
vehicle. Although we observed the higher numbers of
myofibers in the rGDF11-treated group in the absence
of CTX injury (Fig. 1c, left), there was no difference be-
tween these groups upon injury (Fig. 1c, right). Both
GDF11- and vehicle-treated muscles displayed equiva-
lent increase in myofiber numbers following CTX injury
(Fig. 1c), which consisted of small caliber regenerating fi-
bers (Fig. 1d).
Increased rGDF11 levels have no effect on muscle
contractility
To assess whether increased rGDF11 levels would improve
the strength of dystrophic muscles, we measured the con-
tractile properties of the TA muscles from rGDF11- and
vehicle-treated mdx mice. No significant differences were
observed in absolute or specific force (Fig. 3a, b), fatigue
index (Fig. 3c), muscle weight, or CSA (Fig. 3d, e) between
groups, both in the absence and in the presence of cardio-
toxin injury.
Fig. 4 Assessment of fibrosis upon GDF11 treatment. a Representative images of the TA muscles stained with Masson’s trichrome. The presence
of blue between myofibers represents collagen content, which is indicative of fibrosis. b Quantification of fibrosis shows GDF11-treated mice
present increased levels of muscle collagen content in comparison with vehicle-treated mice. As expected, collagen content increased upon
CTX injury, however, only in vehicle-treated mice. Scale bar = 100 μm. **p < 0.01, ****p < 0.0001
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Higher collagen content in rGDF11-treated mice
To determine levels of fibrosis, we evaluated collagen con-
tent in rGDF11- and vehicle-treated dystrophic muscles by
Masson’s trichrome staining. Surprisingly, collagen content
was significantly higher in the rGDF11-treated group when
compared to that in the vehicle control (Fig. 4), which was
not found to further increase upon CTX injury. On the
other hand, injury in the vehicle group resulted in en-
hanced collagen content (Fig. 4b). No significant differ-
ences were observed between rGDF11 and vehicle groups
in the presence of CTX (Fig. 4b) or in the diaphragm
(Fig. 2b), suggesting that maximal levels of fibrosis had
been already reached for the GDF11 group.
The role of GDF11 in skeletal muscle regeneration has
been controversial [8, 12, 15–18]. While the previous
report by Sinha et al. demonstrated that systemic injec-
tion of rGDF11 reverses age-related dysfunction in the
skeletal muscle [5], more recent studies, published while
our study was in progress, contradict this rejuvenating
effect [15, 16]. In fact, the latter agree with previous
publications describing GDF11 as a negative regulator of
myogenesis [17, 18], similar to its homologue, myostatin.
Two recent publications by Egerman et al. [15] and
Rodgers and Eldridge [16] reported that some of the
assays previously used to detect GDF11 [5] were not
specific, and that GDF11 has an inhibitory effect on
muscle regeneration inhibition and that levels of GDF11
actually increase with age. In response to this, Poggioli et al.
have recently reported that the apparent age dependent
increase in GDF11 levels, reported by Egerman et al. [15],
is due to cross reactivity of the anti-GDF11 antibody
with immunoglobulin, which is known to increase with
age [19].
Despite this controversy in the activity of GDF11 in
the context of aging, we addressed here whether GDF11
would have the ability to ameliorate the muscle wasting
phenotype in the context of muscular dystrophy, by pro-
moting muscle regeneration. Although daily doses of
GDF11 treatment for 1 month resulted in elevated levels
of this factor in the plasma, we were not able to detect
any beneficial effect on the histology or strength in the
muscles of treated dystrophic mice. We did not observe
differences in terms of numbers of regenerating centrally
nucleated myofibers. In contrast, we did observe an in-
crease of collagen content, which denotes fibrosis, in the
TA muscle of rGDF11-treated dystrophic mice com-
pared to vehicle-injected controls.
Conclusions
Our study shows no beneficial effect of treating dys-
trophic mice with rGDF11 and raises caution to a
potential harmful effect, as shown by the pro-fibrotic
outcome.
Additional file
Additional file 1: Representative western blot analysis for rGDF11- and
vehicle-injected mdx mice. Plasma was collected from mdx mice that had
been treated with rGDF11 or vehicle for 30 days. (a) Equal amounts (75 μg)
of protein for each mouse were loaded onto each lane. We used the GDF11
antibody from Abcam, which recognizes both the mature dimer (~25 kDa)
and the monomer (~12.5 kDa) of both recombinant GDF11 and myostatin.
We found increased levels of both the monomer and the dimer in the
plasma of rGDF11-treated mice. Recombinant GDF11 (rGDF11) was loaded
as positive control. (b) Stain-free detection of loaded proteins. (PDF 62 kb)
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